Viagenpumatucel-L: Phase Ib/II data

Top-line data from 3 patients with advanced NSCLC previously treated with >=1 prior therapy in the open-label, U.S. Phase Ib/II DURGA

Read the full 218 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE